Masimo Soars 34% on $9.9 Billion Danaher Acquisition at $180 Per Share
Masimo shares jumped 34.22% to $174.69 after Danaher agreed to acquire the company for $9.9 billion at $180 per share, a 38.3% premium to its pre-deal closing price. The merger, expected to close in H2 2026, will keep Masimo as an autonomous unit within Danaher’s Diagnostics segment.
1. Acquisition Agreement Details
Masimo and Danaher signed a definitive agreement under which Danaher will acquire Masimo for $180 per share, valuing the transaction at approximately $9.9 billion, representing a 38.3% premium over Masimo’s February 13 closing price.
2. Stock Performance Reaction
On February 17, Masimo shares surged 34.22% to $174.69, reversing a two-day decline as investors responded to the merger announcement and the premium valuation offered by Danaher.
3. Post-Merger Operations
Upon closing in the second half of 2026, Masimo will operate as a standalone business unit within Danaher’s Diagnostics segment, retaining its brand identity and autonomy in developing patient monitoring technologies.
4. Strategic Rationale
The deal aims to leverage Danaher’s global scale and resources to accelerate commercialization of Masimo’s innovations, enhance investment in talent and R&D, and expand the reach of its monitoring solutions worldwide.